Last reviewed · How we verify
L-alanine
L-alanine is a non-essential amino acid that serves as a substrate for protein synthesis and gluconeogenesis, supporting cellular metabolism and energy production.
L-alanine is a non-essential amino acid that serves as a substrate for protein synthesis and gluconeogenesis, supporting cellular metabolism and energy production. Used for Nutritional supplementation, Metabolic support in clinical nutrition.
At a glance
| Generic name | L-alanine |
|---|---|
| Sponsor | Keith D Lindor, M.D. |
| Drug class | Amino acid supplement |
| Modality | Small molecule |
| Therapeutic area | Nutrition / Metabolic support |
| Phase | FDA-approved |
Mechanism of action
L-alanine is a branched-chain amino acid precursor and gluconeogenic substrate that plays a central role in the glucose-alanine cycle, facilitating the transfer of nitrogen from muscle to liver for glucose production. It is utilized in protein synthesis and serves as an energy source for various tissues. As a marketed nutritional supplement and pharmaceutical ingredient, it supports metabolic function and is used in clinical nutrition formulations.
Approved indications
- Nutritional supplementation
- Metabolic support in clinical nutrition
Common side effects
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Glutathione in Mild Cognitive Impairment (EARLY_PHASE1)
- Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (PHASE1)
- 30 Day Insulin Balance Metabolic Health Optimization Protocol (NA)
- An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |